Key Events This Week
16 Feb: Stock opens at Rs.29.95, marginally down
17 Feb: Positive Q4 2025 financial turnaround announced
17 Feb: Valuation shifts to very attractive amid mixed market performance
18 Feb: Sharp decline of 3.83% on heavy volume
19 Feb: Recovery rally of 3.28% despite Sensex fall
20 Feb: Week closes at Rs.29.03, down 1.93% on the day
16 February 2026: Week Opens with Slight Decline
Link Pharma Chem Ltd started the week at Rs.29.95, down 0.13% from the previous Friday’s close of Rs.29.99. The stock traded on low volume of 14 lakh shares, while the Sensex gained 0.70% to close at 36,787.89. The initial dip reflected cautious investor sentiment ahead of the company’s quarterly results announcement.
17 February 2026: Positive Q4 Financial Turnaround and Valuation Shift
On 17 February, Link Pharma Chem Ltd reported a notable financial turnaround for Q4 2025, with net sales rising 28.4% to ₹13.02 crores for the half-year and operating profit margins expanding to 10.25%. Profit After Tax reached ₹0.09 crores, marking a positive swing from previous quarters. Despite these encouraging fundamentals, the stock closed slightly lower at Rs.29.80 (-0.50%) on increased volume of 80 lakh shares, as investors digested the mixed signals.
Simultaneously, the company’s valuation metrics improved significantly. The price-to-book value compressed to 1.02, and the EV/EBITDA multiple stood at 13.68, considerably lower than many peers. This shift to a “very attractive” valuation status contrasted with the elevated P/E ratio of 95.0, reflecting earnings volatility. The Mojo Score was upgraded to 32.0 with a “Sell” grade, signalling cautious optimism despite ongoing operational challenges.
Quarter after quarter, this Small Cap from the Lifestyle sector delivers without fail! Just added to our Reliable Performers with proven staying power. Stability meets growth here beautifully.
- - Consistent quarterly delivery
- - Proven staying power
- - Stability with growth
18 February 2026: Sharp Decline on Heavy Volume
The stock experienced a sharp decline of 3.83% to Rs.28.66 on 18 February, accompanied by a surge in volume to 1,643 lakh shares. This drop contrasted with the Sensex’s 0.43% gain to 37,062.35, indicating stock-specific selling pressure. The decline likely reflected investor concerns over the company’s operational risks, including a deteriorating debtors turnover ratio of 5.07 times, which signals slower receivables collection and potential liquidity strain.
19 February 2026: Recovery Rally Amid Market Weakness
Link Pharma Chem Ltd rebounded strongly on 19 February, gaining 3.28% to close at Rs.29.60 on volume of 241 lakh shares. This recovery occurred despite a 1.45% drop in the Sensex to 36,523.88, highlighting relative resilience. The bounce may have been driven by renewed investor interest following the positive quarterly results and valuation appeal, although the stock remained below its week’s opening level.
20 February 2026: Week Ends with Moderate Loss
The week concluded with the stock falling 1.93% to Rs.29.03 on 61 lakh shares traded, while the Sensex gained 0.41% to 36,674.32. The closing price marked a 3.20% decline from the previous Friday’s close of Rs.29.99, underperforming the benchmark index by 3.59 percentage points. The modest sell-off reflected lingering caution amid mixed financial signals and the company’s longer-term underperformance relative to the Sensex.
Holding Link Pharma Chem Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Comparison: Link Pharma Chem Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-16 | Rs.29.95 | -0.13% | 36,787.89 | +0.70% |
| 2026-02-17 | Rs.29.80 | -0.50% | 36,904.38 | +0.32% |
| 2026-02-18 | Rs.28.66 | -3.83% | 37,062.35 | +0.43% |
| 2026-02-19 | Rs.29.60 | +3.28% | 36,523.88 | -1.45% |
| 2026-02-20 | Rs.29.03 | -1.93% | 36,674.32 | +0.41% |
Key Takeaways
Positive Signals: Link Pharma Chem Ltd’s Q4 2025 results demonstrated a clear financial turnaround with 28.4% revenue growth and improved operating margins reaching 10.25%. The company’s valuation metrics have shifted favourably, with a P/BV near 1.02 and EV/EBITDA multiple of 13.68, making it relatively attractive compared to peers. The Mojo Score upgrade to 32.0 and a “Sell” grade from “Strong Sell” reflects moderated risk perception.
Cautionary Factors: Despite the improved financials, the stock declined 3.20% over the week, underperforming the Sensex by a wide margin. The sharp drop on 18 February amid heavy volume highlights investor concerns about operational risks, particularly the deteriorating debtors turnover ratio of 5.07 times, which could pressure liquidity. Profitability remains modest with negative ROCE and low ROE, and the stock’s long-term underperformance relative to the Sensex underscores persistent challenges.
Conclusion
Link Pharma Chem Ltd’s week was marked by a mix of encouraging financial results and valuation improvements offset by notable share price weakness. The company’s positive quarterly turnaround and more attractive valuation metrics have not yet translated into sustained investor confidence, as reflected in the 3.20% weekly decline against a Sensex gain of 0.39%. Operational challenges, including slower receivables and modest profitability, continue to weigh on the stock’s performance.
Investors should monitor the company’s ability to maintain margin expansion and improve working capital management to support a more durable recovery. While the valuation reset offers some appeal, the stock’s longer-term underperformance and sector volatility warrant a cautious stance. Continued scrutiny of upcoming earnings and operational metrics will be essential to assess whether Link Pharma Chem can convert its recent positive momentum into consistent shareholder value.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
